An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10) in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma.
Phase of Trial: Phase I
Latest Information Update: 24 Nov 2014
At a glance
- Drugs Lorvotuzumab mertansine (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors ImmunoGen
- 20 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jan 2014 Planned End Date changed from 1 Jul 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.
- 22 Apr 2013 Planned End Date changed from 1 Jan 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.